Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Matula, Kasia ^a   Collie Duguid, Elaina ^a   Murray, Graeme ^a   Parikh, Khyati ^a   Grabsch, Heike ^b   Tan, Patrick ^c   Lalwani, Salina ^a   Garau, Roberta ^a   Ong, Yuhan ^a   Bain, Gillian ^a   Smith, Asa Dahle ^a   Urquhart, Gordon ^a   Bielawski, Jacek ^d   Finnegan, Michael ^a   Petty, Russell ^e  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Chemoresistance; Gastroesophageal cancer; Sphingosine kinase 1; Sphingosine 1 phopshate lyase; Sphingosine 1 phosphate

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; GLYCOSPHINGOLIPID; MESSENGER RNA; OXALIPLATIN; PROTEIN P53; SAFINGOL; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE LYASE; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG; LYASE; LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; RNA; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE 1-PHOSPHATE LYASE (ALDOLASE); SPHINGOSINE KINASE;

ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; ENZYME REGULATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; EXON; GASTROESOPHAGEAL CANCER; GENE; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IMMUNOHISTOCHEMISTRY; LYSOSOME; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SGPL1 GENE; SIGNAL TRANSDUCTION; SPHINGOLIPID METABOLISM; SPHK1 GENE; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL TIME; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DRUG RESISTANCE; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TUMOR CELL LINE;

ALDEHYDE-LYASES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYSOPHOSPHOLIPIDS; MALE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SIGNAL TRANSDUCTION; SPHINGOSINE; STOMACH NEOPLASMS;

EID: 84944688789     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1718-7     Document Type: Article

References (53)

1. Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol. 2012;30(28):3507-15.
2. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and Oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
3. Cunningham D, Allum W, Stenning S, Thompson J, VandeVelde CH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.
4. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903-9.
5. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991-7.
6. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011;141(2):476-85. e11.
7. Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, et al. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut. 2013;62(1):22-33.
8. Bang Y, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.
9. Lordick F, Kang Y, Chung H, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490-9.
10. Waddell T, Chau I, Cunningham D, Gonzalez D, Frances A, Okines C, et al. Epirubicin, Oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):481-9.
11. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968-76.
12. Ohtsu A, Ajani JA, Bai Y, Bang Y, Chung H, Pan H, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31(31):3935-43.
13. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab Monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31-9.
14. Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013;105(7):452-8.
15. Bain GH, Collie-Duguid E, Murray GI, Gilbert FJ, Denison A, Mckiddie F, et al. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas. Br J Cancer. 2014;110(6):1525-34.
16. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1-13.
17. Bielawski J, Pierce J, Snider J, Rembiesa B, Szulc Z, Bielawska A: Comprehensive Quantitative Analysis of Bioactive Sphingolipids by High-Performance Liquid Chromatographyâ€"Tandem Mass Spectrometry. In Volume 579. Edited by Armstrong D. Humana Press; 2009:443-467.
18. Waterworth A, Hanby A, Speirs V. A novel cell array technique for high-throughput, cell-based analysis. In Vitro Cell Dev Biol Anim. 2005;41(7):185-7.
19. Pan J, Tao Y, Zhou Z, Cao B, Wu S, Zhang Y, et al. An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. J Transl Med. 2011;9(1):157.
20. Li W, Yu C, Xia J, Zhang L, Weng G, Zheng H, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2009;15(4):1393-9.
21. Zhang Y, Wang Y, Wan Z, Liu S, Cao Y, Zeng Z. Sphingosine kinase 1 and cancer: a systematic review and meta-analysis. PLoS ONE. 2014;9(2):e90362.
22. Abuhusain HJ, Matin A, Qiao Q, Shen H, Kain N, Day BW, et al. A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis. J Biol Chem. 2013;288(52):37355-64.
23. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res. 2009;69:6915-23.
24. Young N, Pearl DK, Van Brocklyn J. Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61. Mol Cancer Res. 2009;7:23-32.
25. Sarkar S, Maceyka M, Hait NC, Paugh SW, Sankala H, Milstien S, et al. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett. 2005;579:5313-7.
26. Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O. First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther. 2012;11(9):1841-51.
27. Cuvillier O, Pirianov G, Kleuser B. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996;381:800-3.
28. Song L, Xiong H, Li M, Liao WT, Wang L, Wu J. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-{kappa}B pathway in human Non-small cell lung cancer. Clin Cancer Res. 2011;17(7):1839-49.
29. Kohno M, Momoi M, Oo ML, Paik JH, Lee YM, Venkataraman K, et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol. 2006;26:7211-23.
30. Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res. 2013;19(1):138-47.
31. Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, et al. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 2010;70(21):8651-61.
32. Bektas M, Johnson S, Poe W, Bigner D, Friedman H. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. Cancer Chemother Pharmacol. 2009;64(5):1053-8.
33. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther. 2009;8(4):809-20.
34. Nemoto S, Nakamura M, Osawa Y, Kono S, Itoh Y, Okano Y, et al. Sphingosine kinase isoforms regulate Oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J Biol Chem. 2009;284:10422-32.
35. Sukocheva O, Wang L, Verrier E, Vadas MA, Xia P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology. 2009;150:4484-92.
36. Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissié J, Kohama T, et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther. 2008;7(7):1836-45.
37. Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O. First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther. 2012;11:1841-51.
38. Dickson MA, Carvajal RD, Merrill AH, Gonen M, Cane LM, Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res. 2011;17(8):2484-92.
39. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22(1):50-60.
40. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther. 2009;8:809-20.
41. Cuvillier O. Sphingosine in apoptosis signaling. Biochim Biophys Acta. 2002;1585:153-62.
42. Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, Feng F, et al. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol. 2006;173:301-10.
43. Rex K, Jeffries S, Brown ML, Carlson T, Coxon A, Fajardo F, et al. Sphingosine kinase activity is Not required for tumor cell viability. PLoS ONE. 2013;8(7):e68328.
44. Calabresi PA, Radue E, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545-56.
45. Kedderis LB, Bozigian HP, Kleeman JM, Hall RL, Palmer TE, Harrison Jr SD, et al. Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fundam Appl Toxicol. 1995;25(2):201-17.
46. Coward J, Ambrosini G, Musi E, Truman JP, Haimovitz-Friedman A, Allegood JC, et al. Safingol (l-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy. 2009;5:184-93.
47. Hoffmann TK, Leenen K, Hafner D, Balz V, Gerharz CD, Grund A, et al. Antitumor activity of protein kinase C inhibitors and cisplatin in human head and neck squamous cell carcinoma lines. Anti-Cancer Drugs. 2002;13(1):93-100.
48. Gordon MS, Just R, Rosen LS, Dorr A. A phase 1 study of sonepcizumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors. J Clin Oncol. 2010;28(219s):15S.
49. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006;9:225-38.
50. Schwartz GK, Jiang J, Kelsen D, Albino AP. Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst. 1993;85(5):402-7.
51. Banno Y, Kato M, Hara A, Nozawa Y. Evidence for the presence of multiple forms of Sph kinase in human platelets. Biochem J. 1998;335:301-4.
52. Stoffel W, Hellenbroich B, Heimann G. Properties and specificities of sphingosine kinase from blood platelets. Hoppe Seylers Z Physiol Chem. 1973;354(10-11):1311-6. 1973, 354(10-11):1311-16.
53. Orr Gandy KA, Obeid LM. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors. Biochim Biophys Acta. 2013;1831(1):157-66.